Hyperuricemia Market

• The Hyperuricemia Market Size is anticipated to grow with a significant CAGR during the study period (2019-2032).
• Hyperuricemia companies are focusing on innovative treatments to manage high uric acid levels, a condition linked to gout and kidney problems. Key players include Savient Pharmaceuticals, Horizon Therapeutics, Regeneron Pharmaceuticals, and others.
• In August 2024, Shanton Pharma announced the full enrollment of its Phase IIb study for the investigational drug SAP-001, with topline data expected in Q1 2025.

DelveInsight's "Hyperuricemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hyperuricemia, historical and forecasted epidemiology as well as the Hyperuricemia therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hyperuricemia market report provides current treatment practices, emerging drugs, Hyperuricemia market share of the individual therapies, current and forecasted Hyperuricemia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hyperuricemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hyperuricemia market.

Hyperuricemia Treatment Market

The DelveInsight’s Hyperuricemia market report gives a thorough understanding of the Hyperuricemia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Hyperuricemia Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Hyperuricemia.

Hyperuricemia Treatment

It covers the details of conventional and current medical therapies available in the Hyperuricemia market for the treatment of the condition. It also provides Hyperuricemia treatment algorithms and guidelines in the United States, Europe, and Japan. Recent Hyperuricemia clinical trials focus on exploring novel therapies to manage elevated uric acid levels, aiming to improve patient outcomes by reducing gout flare-ups and preventing long-term complications.

Hyperuricemia Epidemiology 

The Hyperuricemia epidemiology section provides insights about the historical and current Hyperuricemia patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Hyperuricemia market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hyperuricemia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

• The prevalence of hyperuricemia in the US is estimated to be around 20.7%
• Among males, the prevalence of hyperuricemia was found to be approximately 19.6%, while in females, it is around 21.8%, with women accounting for nearly 52% of the total cases
• According to a study, the prevalence of hyperuricemia was found to be approximately 17.6% in individuals aged 20–39 years, 18.3% in those aged 40–59 years, and 27.4% in those ≥60 years
• The prevalence of hyperuricemia was found to be approximately 9.7% in the overall adult German population, with 14.7% in men and 2.8% in women
• The prevalence of hyperuricemia in Italy was observed to be approximately 88 per 1,000 inhabitants
• The prevalence of hyperuricemia was observed to be approximately 16.3% in Spain, with a higher prevalence in men

Country Wise- Hyperuricemia Epidemiology

The epidemiology segment also provides the Hyperuricemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hyperuricemia Drug Chapters

The drug chapter segment of the Hyperuricemia report encloses the detailed analysis of Hyperuricemia marketed drugs and late-stage (Phase-III and Phase-II) Hyperuricemia pipeline drugs. It also helps to understand the Hyperuricemia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The hyperuricemia drugs market is witnessing significant growth due to rising cases of gout and kidney disorders, increasing awareness, and ongoing development of innovative therapies targeting uric acid metabolism pathways.

Hyperuricemia Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Hyperuricemia treatment.

Hyperuricemia Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Hyperuricemia treatment.

The hyperuricemia treatment pipeline has made considerable progress, with several companies actively working on drug development. Key advancements include tigulixostat (LC350189) and SAP-001, along with other promising candidates in the works.

Tigulixostat (LC350189) - LG Chem

LC350189 is a novel non-purine selective inhibitor of Xanthine Oxidase (XO). XO is needed to successively oxidize both hypoxanthine and xanthine to uric acid, hence the agent reduces uric acid concentrations in serum by inhibiting the production of uric acid by XO inhibition.

SAP-001 - Shanton Pharma

SAP-001 is a novel small molecule once-a-day investigational product for asymptomatic hyperuricemia. SAP-001 has urate lowering properties that is based on a unique mechanism-of-action. It is being investigated in Phase IIb trial in subjects gout, and hyperuricemia refractory to conventional XOI therapy. However, as per company’s pipeline it is also being developed for asymptomatic hyperuricemia in Phase II trial.

Hyperuricemia Market Outlook

The Hyperuricemia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hyperuricemia market trends by analyzing the impact of current Hyperuricemia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Hyperuricemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hyperuricemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

• The prevalence of Hyperuricemia is found in 6.3% of the global population 
• The most complication of Hyperuricemia is gout which is seen in 3.9% of the population in the United States of America
• The most common cause of Hyperuricemia is Alcohol Consumption, which results in the accelerated hepatic breakdown of ATP and generation of the organic acids in the body 
• The prevalence of gout due to hyperuricemia is rare, people with Uric acid levels above 9mg/dL are prone to develop gout

According to DelveInsight, the Hyperuricemia market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Hyperuricemia market in 7MM.

The United States Hyperuricemia Market Outlook

This section provides the total Hyperuricemia market size and market size by therapies in the United States.

EU-5 Countries Hyperuricemia Market Outlook

The total Hyperuricemia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Hyperuricemia Market Outlook

The total Hyperuricemia market size and market size by therapies in Japan is also mentioned.

Hyperuricemia Drugs Uptake

This section focuses on the rate of uptake of the potential Hyperuricemia drugs recently launched in the Hyperuricemia market or expected to get launched in the market during the study period 2019-2032. The analysis covers Hyperuricemia market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Hyperuricemia Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Hyperuricemia market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hyperuricemia Pipeline Development Activities

The Hyperuricemia pipeline report provides insights into different Hyperuricemia clinical trials within Phase II, and Phase III stage. It also analyses Hyperuricemia key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Hyperuricemia clinical trials analysis report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Hyperuricemia emerging therapies.

Reimbursement Scenario in Hyperuricemia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Hyperuricemia market trends, we take KOLs and SMEs ' opinion working in the Hyperuricemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Hyperuricemia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Hyperuricemia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Hyperuricemia Market Report

• The report covers the descriptive overview of Hyperuricemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Hyperuricemia epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Hyperuricemia is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Hyperuricemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hyperuricemia market

Hyperuricemia Market Report Highlights

• In the coming years, the Hyperuricemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Hyperuricemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Hyperuricemia. The launch of emerging therapies will significantly impact the Hyperuricemia market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hyperuricemia
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hyperuricemia Market Report Insights

• Hyperuricemia Patient Population
• Hyperuricemia Therapeutic Approaches
• Hyperuricemia Pipeline Analysis
• Hyperuricemia Market Size and Trends
• Hyperuricemia Market Opportunities
• Impact of upcoming Hyperuricemia Therapies

Hyperuricemia Market Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Hyperuricemia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Hyperuricemia Drugs Uptake

Hyperuricemia Market Report Assessment

• Current Hyperuricemia Treatment Practices
• Hyperuricemia Unmet Needs
• Hyperuricemia Pipeline Product Profiles
• Hyperuricemia Market Attractiveness
• Hyperuricemia Market Drivers
• Hyperuricemia Market Barriers

Key Questions Answered In The Hyperuricemia Market Report:

Hyperuricemia Market Insights:

• What was the Hyperuricemia drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Hyperuricemia total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Hyperuricemia market size during the forecast period (2019-2032)?
• At what CAGR, the Hyperuricemia market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Hyperuricemia market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Hyperuricemia market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Hyperuricemia Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Hyperuricemia?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Hyperuricemia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Hyperuricemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hyperuricemia?
• Out of all 7MM countries, which country would have the highest prevalent population of Hyperuricemia during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Hyperuricemia Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Hyperuricemia treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Hyperuricemia in the USA, Europe, and Japan?
• What are the Hyperuricemia marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many Hyperuricemia companies are developing therapies for the treatment of Hyperuricemia?
• How many therapies are in-development by each company for Hyperuricemia treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Hyperuricemia treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Hyperuricemia therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hyperuricemia and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Hyperuricemia?
• What are the global historical and forecasted market of Hyperuricemia?

Reasons to buy Hyperuricemia Market Forecast Report

• The report will help in developing business strategies by understanding trends shaping and driving the Hyperuricemia market
• To understand the future market competition in the Hyperuricemia market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Hyperuricemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Hyperuricemia market
• To understand the future market competition in the Hyperuricemia market